BOSTON, April 13 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has successfully completed Phase One requirements for the Company’s ISO 13485 quality management system (QMS) initiative. The project is divided into four phases, each with predetermined deliverables. Compliance with ISO 13485 is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union, which represents $94 Billion, or 30%, of the worldwide demand for medical instruments, according to a 2009 Frost & Sullivan report.
“We are pleased to have completed the first phase of such an important project and milestone for the company,” stated Bob Segersten, President of Solos Endoscopy, Inc. “And we are on track with our plan for completion of the QMS initiative in the third quarter of 2010.”
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company’s website at: www.solosendoscopy.com.
CONTACT: Investor Relations of Solos Endoscopy, Inc., +1-407-389-5900
Web site: http://www.solosendoscopy.com/
